Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine 2001 March;45(1) > The Quarterly Journal of Nuclear Medicine 2001 March;45(1):7-17

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

  NUCLEAR MEDICINE APPLICATIONS FOR BONE METASTASESFREEfree


The Quarterly Journal of Nuclear Medicine 2001 March;45(1):7-17

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

Clinical utility of biochemical marker of bone remodelling in patients with bone metastases of solid tumors

Seregni E., Martinetti A., Ferrari L., Bombardieri E.

From the Nuclear Medicine Division Istituto Nazionale per lo Studio e la Cura dei Tumori Milan, Italy


FULL TEXT  


Bone turn­over is char­ac­ter­ized ­both by the for­ma­tion of new ­bone by the oste­o­blasts and the resorp­tion of old tis­sue by the oste­o­clast. This pro­cess ­takes ­place ­only on the sur­face of ­bone and can be ­described in ­terms of spa­tio-tem­po­ral ­events ­that are the ­bone meta­bol­ic ­unit and the ­bone remod­el­ling ­cycle. The for­mer con­sists of a dis­crete ­group of ­cells (oste­o­blasts and oste­o­clasts) ­involved in a par­tic­u­lar remod­el­ling ­event ­while the lat­ter rep­re­sents the suc­ces­sion of resorp­tion and for­ma­tion. In a typ­i­cal remod­el­ling ­cycle, resorp­tion ­takes 7-10 ­days, where­as for­ma­tion ­requires 2-3 ­months. Remodelling is reg­u­lat­ed ­either by ­local or system­ic fac­tors, includ­ing electri­cal and mechan­i­cal forc­es, hor­mones (e.g. para­thy­roid hor­mone, sex­u­al ster­oids, cal­cit­ri­ol, cor­ti­sol, thy­roid hor­mones, cal­cit­o­nin), ­growth fac­tors and cyto­kines. Recently dif­fer­ent cir­cu­lat­ing bio­chem­i­cal mark­ers ­have ­been pro­posed for the inves­ti­ga­tion of ­bone turn­over. In addi­tion to clas­si­cal param­e­ters ­such as ser­um alka­line phos­pha­tase and uri­nary cal­cium and hydrox­y­pro­line, new mark­ers ­have ­gained clin­i­cal atten­tion ­because of ­their accu­ra­cy in assess­ing the dynam­ic chang­es in ­bone remod­el­ling (­bone alka­line phos­pha­tase, oste­o­cal­cin, prope­tides ­PICP and ­PINP, tar­trate-resist­ant ­acid phos­pha­tase, deoxy­py­ri­din­o­line, pyri­din­o­line, tel­opep­tide CTx and NTx). The aim of ­this ­review is to ­present the ­recent advanc­es in ­this ­field and the clin­i­cal appli­ca­tion of mark­ers of ­bone turn­over in ­patients ­with ­bone metas­ta­ses ­from sol­id ­tumors. Also the cel­lu­lar and molec­u­lar bas­es of ­bone remod­el­ling are report­ed ­with ­details.

top of page

Publication History

Cite this article as

Corresponding author e-mail